Tumor-directed therapeutic targets in Cushing disease.

Tumor-directed therapeutic targets in Cushing disease.

J Clin Endocrinol Metab. 2018 Dec 07;:

Authors: Theodoropoulou M, Reincke M

Abstract
Context: The most frequent cause of endogenous hypercortisolism is Cushing disease (CD), a devastating condition associated with severe comorbidities and high mortality. Effective tumor-targeting therapeutics are limited.
Evidence acquisition: Search in PubMed with keywords 'corticotroph' and 'Cushing's disease' plus the name of the mentioned therapeutic agent and in associated references of the obtained papers. In addition, potential therapeutics were obtained from ClinicalTrials.gov with search word 'Cushing disease'.
Evidence synthesis: At present the tumor-targeted pharmacological therapy of CD is concentrated on dopamine agonists (cabergoline) and somatostatin analogs (pasireotide) with varying efficacy, escape from response and considerable side effects. Preclinical studies on corticotroph pathophysiology has brought forward potential drugs like retinoic acid, silibinin and roscovitine, whose efficacy and safety remains to be determined.
Conclusions: For many CD patients, effective tumor targeted pharmacological therapy is still lacking. Coordinated efforts are pivotal in establishing efficacy and safety of novel therapeutics in this rare but devastating disease.

PMID: 30535260 [PubMed - as supplied by publisher]

from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2Ehra1i